Minerva Neurosciences GAAP EPS of -$0.19 misses by $0.01 (NASDAQ:NERV)
Minerva Neurosciences reported Q3 GAAP EPS of -$0.19, missing estimates by $0.01. Cash and equivalents were $77.0M on Sept 30, 2026, down from $82.4M on Dec 31, 2025, according to the company.
How this was made
The 30-second read
Why it matters
The earnings miss is likely to trigger a modest decline in NERV's share price, with limited spillover to the broader biotech sector.
Market read
Primary micro‑cap earnings news; relevant for traders with exposure to small‑cap biotech equities.
What to watch
Cash balance of $77M provides runway; the miss may be a temporary blip pending upcoming trial data.
Background
Minerva Neurosciences (NASDAQ:NERV) reported its Q3 GAAP earnings, showing a slight EPS miss.
Ticker impact
Q3 GAAP EPS of -$0.19 missed expectations by $0.01, disclosed in the press release.
downward pressure as investors price in the EPS miss
The miss is a primary disclosure for a micro‑cap biotech; such news typically triggers a sell‑off.
Market effects
May weigh on other small‑cap biotech stocks awaiting earnings.
Limited to U.S. biotech sector; no broader regional effect.
Low global relevance; impact confined to niche investors.
Counterpoint
If the miss is within a narrow range, the stock could be oversold and present a short‑term buying opportunity.
Key entities
- CompanyMinerva Neurosciences
Biotech firm listed on Nasdaq (NERV).
